Creative Planning Buys 3,749 Shares of Danaher Co. (NYSE:DHR)

Creative Planning increased its stake in Danaher Co. (NYSE:DHR) by 3.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 126,340 shares of the conglomerate’s stock after acquiring an additional 3,749 shares during the period. Creative Planning’s holdings in Danaher were worth $35,125,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Benjamin Edwards Inc. lifted its stake in Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after purchasing an additional 38 shares in the last quarter. Wedge Capital Management L L P NC increased its holdings in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. lifted its position in shares of Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after buying an additional 40 shares in the last quarter. Trust Co of Kansas boosted its stake in Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after buying an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. increased its stake in Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after acquiring an additional 40 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 0.9 %

NYSE DHR opened at $274.38 on Monday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a 50 day moving average price of $270.72 and a 200 day moving average price of $260.13. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market cap of $203.23 billion, a PE ratio of 46.51, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the business posted $2.05 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. TD Cowen increased their target price on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Barclays lifted their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Evercore ISI upped their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Stephens initiated coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target for the company. Finally, Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.